Prudential Financial
TRDA icon

Prudential Financial’s Entrada Therapeutics TRDA Stock Holding History

Prudential Financial’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,340
Closed -$190K – 2528
2025
Q2 		$190K Buy
28,340
+5,370
+23% +$43.2K ﹤0.01% 2218
2025
Q1 		$208K Buy
22,970
+20
+0.1% +$249 ﹤0.01% 2070
2024
Q4 		$397K Hold
22,950
– – ﹤0.01% 1911
2024
Q3 		$367K Buy
+22,950
New +$362K ﹤0.01% 2338

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
Cantor Fitzgerald
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Prudential Financial's TRDA Position: Q3 2025 in Review

Prudential Financial sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 28,340 shares — an estimated $190K sold.

Prudential Financial first reported a position in TRDA in Q3 2024 and held it in 4 quarters. The position peaked at $397K in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Prudential Financial reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prudential Financial sold 28,340 Entrada Therapeutics shares in Q3 2025, an estimated $190K.
  • Prudential Financial first reported a position in Entrada Therapeutics in Q3 2024 and held it in 4 quarters.
  • Prudential Financial's Entrada Therapeutics position peaked at $397K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Prudential Financial's 13F filing for Q3 2025, filed 13 Nov 2025.